<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Degarelix Ferring - Circular Buttons</title>
    <!-- Bootstrap 5.0.2 CSS -->
    <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.0.2/dist/css/bootstrap.min.css" rel="stylesheet">
    <link rel="stylesheet" href="style.css">
</head>

<body>
    <section id="a-different-class-of-adt" class="hero">
        <div class="hero-section">
            <img src="./images/banner.jpg" alt="Banner" class="banner-img">
            <div class="center-img">
                <img src="./images/hero-section-img.png" alt="Hero Section Image">
            </div>

            <div class="nav-buttons-container">
                <div class="nav-btn-container nav-btn-1">
                    <a class="nav-btn-link" href="#section-seven">
                        <div class="nav-icon-container">

                            <img class="nav-icon-img" src="images/icon/c1.png" alt="Navigation Icon">
                        </div>
                        <div class="popup-text-container">
                            <div class="pill-text">A different class of ADT</div>
                        </div>
                    </a>
                </div>

                <div class="nav-btn-container nav-btn-2">
                    <a class="nav-btn-link" href="#section-eight">
                        <div class="nav-icon-container">
                            <img class="nav-icon-img" src="images/icon/c2.png" alt="Navigation Icon">
                        </div>
                        <div class="popup-text-container">
                            <div class="pill-text">Control CVD</div>
                        </div>
                    </a>
                </div>

                <div class="nav-btn-container nav-btn-3">
                    <a class="nav-btn-link" href="#section-six">
                        <div class="nav-icon-container">
                            <img class="nav-icon-img" src="images/icon/c3.png" alt="Navigation Icon">
                        </div>
                        <div class="popup-text-container">
                            <div class="pill-text"> economic burden</div>
                        </div>
                    </a>
                </div>

                <div class="nav-btn-container nav-btn-4">
                    <a class="nav-btn-link" href="#section-five">
                        <div class="nav-icon-container">
                            <img class="nav-icon-img" src="images/icon/c4.png" alt="Navigation Icon">
                        </div>
                        <div class="popup-text-container">
                            <div class="pill-text">Disease related symptoms</div>
                        </div>
                    </a>
                </div>

                <div class="nav-btn-container nav-btn-5">
                    <a class="nav-btn-link" href="#section-one">
                        <div class="nav-icon-container">
                            <img class="nav-icon-img" src="images/icon/c8.png" alt="Navigation Icon">
                        </div>
                        <div class="popup-text-container">
                            <div class="pill-text">Delay progression</div>
                        </div>
                    </a>
                </div>

                <div class="nav-btn-container nav-btn-6">
                    <a class="nav-btn-link" href="#section-two">
                        <div class="nav-icon-container">
                            <img class="nav-icon-img" src="images/icon/c7.png" alt="Navigation Icon">
                        </div>
                        <div class="popup-text-container">
                            <div class="pill-text">What do patients think?</div>
                        </div>
                    </a>
                </div>

                <div class="nav-btn-container nav-btn-7">
                    <a class="nav-btn-link" href="#section-three">
                        <div class="nav-icon-container">
                            <img class="nav-icon-img" src="images/icon/c6.png" alt="Navigation Icon">
                        </div>
                        <div class="popup-text-container">
                            <div class="pill-text">Support & resource</div>
                        </div>
                    </a>
                </div>

                <div class="nav-btn-container nav-btn-8">
                    <a class="nav-btn-link" href="#section-four">
                        <div class="nav-icon-container">
                            <img class="nav-icon-img" src="images/icon/c5.png" alt="Navigation Icon">
                        </div>
                        <div class="popup-text-container">
                            <div class="pill-text">licence</div>
                        </div>
                    </a>
                </div>
            </div>

            <div class="hero-lower-text DEGARELIX-Nova">
                To navigate the website, click on any of the icons around the heart
            </div>
        </div>
    </section>


    <section id="control-cvd" class="second">
        <div class="container-fluid position-relative">
            <img src="./images/second-section.png" class="floating-bg" alt="">

            <div class="container second-container text-center position-relative z-1">
                <div class="row justify-content-center">
                    <div class="col-12">
                        <h1 class="mb-2 adt-heading DEGARELIX-Nova"> <span>DEGARELIX FERRING</span> is a different class
                            of <br class="d-none d-md-block">
                            <span>ADT</span><sup>1</sup>
                        </h1>
                        <p class="mb-5 DEGARELIX-Mt">HSPC (hormone sensitive prostate cancer) can be treated with...</p>

                        <div class="box DEGARELIX-Nova ">
                            <div class="box1 col-12 col-lg-6 d-flex  flex-column align-items-center">
                                <div class="DEGARELIX-Mt">
                                    <strong class="highlight-text DEGARELIX-Nova ">LHRH agonists</strong> that
                                    overstimulate
                                    gonadotrophin releasing hormone (GnRH)
                                    receptors and rely on a negative feedback to
                                    achieve testosterone suppression, but may cause
                                    an initial clinical flare
                                </div>
                            </div>
                            <div class="box2 col-12 col-lg-6 d-flex  flex-column align-items-center">
                                <div>
                                    <strong>DEGARELIX FERRING</strong>, a GnRH antagonist that blocks GnRH receptors
                                    directly, enabling rapid
                                    testosterone suppression.
                                </div>
                            </div>
                        </div>

                        <button class="mt-4 button">More on the MoA of Degarelix Ferring</button>
                    </div>
                </div>
            </div>
        </div>
    </section>

    <section id="economic-burden" class="third position-relative w-100 overflow-hidden">
        <div class="position-absolute top-0 end-0">
            <img src="./images/third-section.png" class="floating-bg" alt="">
        </div>


        <div class="container text-center third-container">
            <p class="DEGARELIX-Mt">
                <strong class="DEGARELIX-Nova">CVD</strong> is the leading cause of death in prostate cancer
                patients,<br>
                after prostate cancer itself <sup>2,3</sup>
            </p>


            <div class="position-relative  mx-auto ">
                <div class="d-flex justify-content-center align-items-start">
                    <div class="position-relative  d-flex flex-column align-items-start position-relative">
                        <div class="card1">
                            <img src="./images/card1.png" class="img-fluid card1-img" alt="">
                        </div>

                        <div class="card3 position-absolute ">
                            <img src="./images/card3.png" class="img-fluid mx-2 card3-img" alt="">
                        </div>
                    </div>


                    <div class="card2 ">
                        <img src="./images/card2.png" class="img-fluid card2-img" alt="">
                    </div>
                </div>
            </div>


            <div class="desp  DEGARELIX-Nova">
                <p class="mt-1">
                    Up to <strong class="highlight-percentage fs-1">30%</strong> of prostate cancer patients are likely
                    to be at high risk of a CV event <sup>4,5</sup>
                </p>
            </div>


            <button class=" button">Learn How Degarelix Ferring Helps Control CVD Risk</button>
        </div>
    </section>

    <section id="disease-related-symptoms" class="fourth DEGARELIX-Mt  position-relative  overflow-hidden">
        <div class="position-absolute top-0 end-0">
            <img src="./images/fourth-section-img.png" class="floating-bg" alt="">
        </div>


        <div class="container text-center  fourth-container">
            <p class="fourth-section-heading lh-sm">
                What do you think the <span class="highlight-text">economic burden</span> of CVD
                related events is in the UK?
            </p>


            <div class="mb-4">
                <img src="./images/fourth-section-center-img.png" class="  fourth-container-img " alt="">
            </div>

            <div class="fourth-container-desp mb-5 text-center">
                <p class="fs-6">In England,<span class="highlight-text">every CVD-related event</span> costs the NHS</p>
                <h1> <span class="highlight-text">£3,449</span><sup class="fw-normal">6,7</sup> </h1>
            </div>
            <button class="d-inline-block button  ">Find out the cost of CVD events in your local area</button>
        </div>
    </section>

    <section id="delay-progression" class=" fifth DEGARELIX-Mt position-relative w-100 overflow-hidden ">
        <div class="position-absolute top-0 end-0">
            <img src="./images/fifth-section-img.png" class="floating-bg" alt="">
        </div>

        <div class="container fifth-container text-center ">
            <div class=" text-center  px-5 mb-5">
                <h4 class=" mx-auto text-center lh-sm">
                    <strong> DEGARELIX FERRING</strong> is significantly more
                    effective in controlling <strong>disease-related symptoms</strong> vs. LHRH agonists<sup>8</sup>
                </h4>
            </div>

            <p class=" Note-heading mb-1">Hover / tap below to learn more</p>
            <div class="row justify-content-center mx-auto w-100 mb-4">
                <div class="  custom-box-1 col-12 col-lg-6 d-flex  flex-column align-items-center">
                    <h5 class="  fw-bold">
                        Urinary-tract problems
                    </h5>
                    <div class="d-flex flex-row  w-100">
                        <div class="w-75 text-start p-3">Urinary-associated problems,
                            e.g. obstructive uropathy leading
                            to persistent infections and
                            LUTS</div>
                        <div class="w-25">
                            <img src="./images/fifth-section-card-1.png" class="w-100  my-2" alt="">
                        </div>
                    </div>

                </div>
                <div class=" custom-box-2 col-12   col-lg-6 d-flex  flex-column align-items-center ">
                    <h5 class="   fw-bold">
                        Bone and back pain
                    </h5>
                    <div class="d-flex flex-row w-100">
                        <div class="w-75 text-start p-3">As a result of arthralgia, or
                            eventually bone metastases,
                            which can lead to fractures and
                            spinal cord compression</div>
                        <div class="w-25">
                            <img src="./images/fifth-section-card-2.png" class="w-100  my-2" alt="">
                        </div>
                    </div>
                </div>
            </div>

            <div class="delay-progression-sub-heading">
                <p class="fs-6  mx-auto ">Which of your advanced PC patients would benefit from the
                    <span class="highlight-text">significantly reduced</span> disease related symptoms
                    DEGARELIX FERRING delivers?
                </p>
            </div>

            <div>
                <button class="d-inline-block button  mx-auto mt-5 ">More on improving quality of life</button>
            </div>
        </div>
    </section>

    <section id="what-do-patients-think" class="sixth DEGARELIX-Mt position-relative pb-5">
        <div class="position-absolute top-0 end-0">
            <img src="./images/sixth-section-img.png" class="floating-bg" alt="">
        </div>
        <div class="container  sixth-container ">
            <div class="row">
                <div class="col-md-12  ">
                    <h4 class=" mx-auto disease-progression-heading text-center px-5"> <span>DEGARELIX FERRING</span>
                        can <span>delay disease
                            progression</span><sup>9,10</sup></h4>
                    <p class="standard-section-subheading-text text-center mt-4 ">Time is
                        extremely valuable to you and your patients.</p>
                    <div class="watch-section mx-auto text-center ">
                        <img src="./images/watch.png " class="watch-section-img" alt="">
                        <p class="Note-heading mt-2">Hover / tap above to learn more</p>

                    </div>

                    <p class="three-slide-down-50 slide-down-50 animate_opacity  watch-desp">
                        DEGARELIX FERRING can help give patients <span class="highlight-text">quantity</span>, as
                        well as <span class="highlight-text">quality of life</span><sup>8-10</sup> by increasing
                        PSA progression-free survival at 12 months vs. LHRH agonists.</p>
                    <p class="side-note Note-heading ">**As calculated using the Weibull estimate</p>
                    <div class="text-center">
                        <button class="d-inline-block button  mx-auto my-2 ">More on delaying progression</button>
                    </div>
                </div>

            </div>
    </section>

    <section id="support-and-resource" class="seventh DEGARELIX-Mt  position-relative ">
        <div class="position-absolute top-0 end-0">
            <img src="./images/seventh-section-img.png" class="floating-bg" alt="">
        </div>

        <div class="container seventh-container mx-auto">
            <div class="row patient-think">
                <div class="col-md-12 text-center">
                    <h4 class="mx-auto patient-think-heading px-5">
                        <span class="highlight-text">What do patients think</span> about <span
                            class="highlight-text">DEGARELIX FERRING?</span>
                    </h4>

                    <p class="mt-3">
                        There is <span class="highlight-text">high and sustained patient satisfaction</span> with
                        DEGARELIX FERRING
                        administration.
                        <sup>11</sup>
                    </p>

                    <div class="row justify-content-center m-2 w-100  ">

                        <div class="col-12 col-lg-6 d-flex  flex-column align-items-center cards ">
                            <div class="seven-card-1 text-center d-flex flex-column float-end align-items-center">
                                <img class="img mb-3" src="./images/seventh-img-1.png" alt="">
                                <div class="w-75 mx-auto">
                                    <p class="text-center fw-normal custom-highlight-text mb-0">
                                        Monthly DEGARELIX FERRING administration was
                                        <strong class="highlight-text">considered satisfactory by 82% of
                                            patients</strong>
                                        (173/211) at 6 months<sup>11*</sup>
                                    </p>
                                </div>
                            </div>
                        </div>

                        <div class="col-12 col-lg-6 d-flex  flex-column align-items-center  cards1 ">
                            <div class="seven-card-2 d-flex  flex-column align-items-center  text-center">
                                <img class="img mb-3" src="./images/seventh-img-2.png" alt="">
                                <div class="w-75 mx-auto">
                                    <p>
                                        Satisfaction was <span class="highlight-text">sustained during the maintenance
                                            phase</span>,
                                        with patient satisfaction rate increased to 83.6% (117/140) at 12
                                        months<sup>11</sup>
                                    </p>
                                </div>
                            </div>
                        </div>
                        <p class="text-start Note-heading mt-2">*Patient satisfaction was the secondary endpoint in a
                            multicentre, long-term,
                            prospective, observational, non-interventional study of DEGARELIX FERRING patients in the
                            Netherlands with advanced prostate
                            cancer. The primary endpoint was PFS failure rate.</p>

                    </div>


                    <p class="fs-5 ">Help to ensure your patients also have a <span class="highlight-text">positive
                            experience</span> with
                        Degarelix Ferring administration.</p>
                    <button class="button mt-4">Find out how</button>
                </div>
            </div>

        </div>
    </section>

    <section id="licence" class="eight DEGARELIX-Mt position-relative">
        <div class="container eight-container mx-auto">
            <div class="row">
                <div class="col-12 text-center">
                    <h4 class="main-heading mb-2">DEGARELIX FERRING <span>licence</span></h4>
                    <p class="sub-heading w-75 mx-auto mb-5">
                        DEGARELIX FERRING is a GnRH antagonist approved before or after
                        radiotherapy for patients with
                        <b>high-risk localised or locally advanced hormone-dependent prostate
                            cancer.</b><sup>12,13</sup>
                    </p>
                </div>
            </div>

            <div class="row">
                <div class="col-12">
                    <div class="table-responsive">
                        <table class="table table-bordered text-center custom-table">
                            <thead>
                                <tr>
                                    <th colspan="3" class="localized-header">Localised prostate cancer</th>
                                    <th rowspan="2" class="locally-advanced-header">Locally advanced PCa</th>
                                    <th rowspan="2" class="metastatic-header">Metastatic PCa</th>
                                </tr>
                                <tr>
                                    <th class="low-risk-header">Low Risk</th>
                                    <th class="intermediate-risk-header">Intermediate Risk</th>
                                    <th class="high-risk-header">High Risk</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td class="low-risk-col">PSA <10 ng/mL</td>
                                    <td class="intermediate-risk-col">PSA 10-20 ng/mL</td>
                                    <td class="high-risk-col">PSA >20 ng/mL</td>
                                    <td class="light-orange-col">Any PSA</td>
                                    <td class="light-orange-col">Any PSA</td>
                                </tr>
                                <tr>
                                    <td class="low-risk-col">+ Gleason score <7</td>
                                    <td class="intermediate-risk-col">
                                        <span class="or-separator">OR</span><br />Gleason score =7
                                    </td>
                                    <td class="high-risk-col">
                                        <span class="or-separator text-white">OR</span><br />Gleason score >7
                                    </td>
                                    <td class="light-orange-col">Any Gleason score</td>
                                    <td class="light-orange-col">Any Gleason score</td>
                                </tr>
                                <tr>
                                    <td class="low-risk-col">cT1-2a</td>
                                    <td class="intermediate-risk-col"><span class="or-separator">OR</span> T2b</td>
                                    <td class="high-risk-col">
                                        <span class="or-separator text-white">OR</span> T2c
                                    </td>
                                    <td class="light-orange-col">T3-4 or N1</td>
                                    <td class="light-orange-col">T3/4, N1, M1</td>
                                </tr>
                                <tr>
                                    <td class="no-border bg-transparent"></td>
                                    <td class="no-border bg-transparent"></td>
                                    <td colspan="3" class="footer-row">DEGARELIX FERRING</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                </div>
            </div>

            <p class="text-start Note-heading">
                Adapted from European Association of Urology Guidelines, 2022.
            </p>

            <p class="text-center description-text">
                DEGARELIX FERRING is indicated for the treatment of adult male patients
                with advanced hormone-dependent prostate cancer, also in combination
                with radiotherapy and as neo-adjuvant treatment prior to radiotherapy in
                patients with high-risk localised or locally hormone-dependent dependent
                prostate cancer.<sup>12,13</sup>
            </p>

            <div class="text-center"> <button type="button" class="button mx-auto">Find out how</button></div>
        </div>
    </section>

    <section id="reconstitution-and-administration-video" class="nine DEGARELIX-Mt ">
        <div class="container nine-container mx-auto">
            <div class="row">
                <div class="col-md-12  text-center">
                    <h4 class=" Reconstitution-heading mb-4">
                        Reconstitution and administration video
                    </h4>
                    <div class="new-container  DEGARELIX-Mt  py-2">
                        <div class="my-4">
                            <div class="flex-row-container ">
                                <div class="first-sub text-start">
                                    <p class="first-sub-hed DEGARELIX-Nova Reconstitution-heading ">Reconstitution and
                                        Administration Video
                                        Including Top Tips by Leanne McCourt</p>
                                    <p class="first-sub-desp ">Learn how to best administer a Degarelix Ferring
                                        injection by watching our instructional video with Leanne
                                        McCourt Macmillan Urology Nurse Specialist. This quick
                                        demonstration illustrates the precise technique for
                                        administering a deep subcutaneous injection into the
                                        abdomen.Watch the video now for a comprehensive
                                        understanding of the dosing and administration process</p>

                                </div>
                                <div class="flex-item second-sub p-1 ">
                                    <iframe src="https://player.vimeo.com/video/1097937970?h=109aa2dea2" frameborder="0"
                                        allow="autoplay; fullscreen; picture-in-picture" allowfullscreen
                                        class="w-100 h-100">
                                    </iframe>
                                </div>
                            </div>
                            <div class=" mt-5 text-start mx-4 ">
                                <h5 class="DEGARELIX-Nova Reconstitution-heading">Summary of Top Tips from Leanne</h5>
                                <div class="row">
                                    <div class="three-row-item">
                                        <ol>
                                            <li>Do not reconstitute until ready to administer</li>
                                            <li>Swirl don’t shake during reconstitution</li>
                                            <li>Administer Firmagon immediately after reconstitution</li>
                                            <li>Don’t prime your needle</li>
                                        </ol>

                                    </div>
                                    <div class="three-row-item">
                                        <ol start="5">
                                            <li>Give via a deep subcutaneous injection</li>
                                            <li>Pinch the abdominal skin and vary your site</li>
                                            <li>Avoid sites exposed to friction</li>
                                            <li>Use a 45 to 95 degree angle to insert the needle</li>
                                        </ol>
                                    </div>
                                    <div class="three-row-item">
                                        <ol start="9">
                                            <li>Slowly administer over 30 seconds</li>
                                            <li>Following administration hold the needle in place for a further 30
                                                seconds
                                                and remove slowly</li>
                                            <li>Give the patient self care advice i.e. not to rub or scratch the area
                                                and
                                                use a cold compress</li>
                                        </ol>

                                    </div>
                                </div>

                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>


    <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.0.2/dist/js/bootstrap.bundle.min.js"></script>
</body>

</html>